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1. Introduction 
The thyrotropin releasing hormone (TRH) of the 
hypothalamus which is the tripeptide pyroglutamyl- 
histidylprolinamide (~nGlu-His-Pro--NH2) was the 
first hypothalamic neurohormone to be structurally 
elucidated and synthesized [1,2]. Since TRH is a 
small molecule with great biological importance a 
large number of analogs of the hormone have been 
synthesized and studied in various assay systems 
[3-51. These studies have been very important to 
elucidate the structure function relationship and the 
biochemical mechanism of action of TRH. Another 
approach to the structure -function problem of TRH 
is to define the shape of the molecule and the 
relationship between conformation and biological 
activity. Recently several papers have appeared which 
are concerned with conformations of TRH [6-10].  
This report describes the biological activities of 
four tri-peptides,L-~Glu-Leu Pro-NH2 (1) ,~Glu -  
Leu-Pro-OCH3 (2),L-~Glu-Thi-Pro NH2 (3) and 
~Glu -Th i -P ro -OCH3 (4) (Thi -- fl-(2-thienyl)-L- 
alanine). The chemical properties of these peptides 
appear to add information about the conformation 
of TRH when their biological potencies are evaluated 
together with the recent findings of Burgess et al. [11 ] 
on the low energy conformations of TRH. 
2. Materials and methods 
Peptides 1-4  have been synthesized by classical 
methods in solution as previously described by 
Sievertsson et al. [121 • The assays for TSH release in 
vivo in mice have been performed using the T 3-TRH 
method of Bowers et al. [13,14]. 
To measure the in vitro effect of TRH and its 
analogs, 2 pituitaries obtained from 20-day-old female 
Sprague-Dawley rats (Charles River Laboratory) 
were incubated at 37°C in 1 ml of lactated Ringer's 
glucose (1 mg/ml) medium (Travenol Laboratories) 
in 10 ml Teflon beakers in a Dubnoff shaker. 
Pituitaries were incubated for a total of 6 hr. Medium 
was removed each hour for R1A of TSH and fresh 
medium was added. After two pre-incubation periods 
(1 hr each), the peptides were added each hour. 
Each analog was measured in duplicate by the 
NIAMDD method of Parlow (personal communication). 
TSH is reported in equivalents of NIAMDD rat TSH- 
RP-1 which has a biological potency of 0.22 USP 
(Bovine) TSH Units/mg by the McKenzie Assay. 
(The nomenclature of the amino acids and peptides 
are following the IUPAC-IUB recommendations 
1972). 
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3. Results and discussion 
The data on the thyrotropin (TSH) induced 
release in vivo in mice are presented in table 1. Leu 2 -  
TRH (1) has about 2% of the activity of TRH while 
Thi 2 -TRH (3) show up to 31Y~ hormonal activity. 
However, none of the peptides have a dose-response 
curve parallel to that of TRH. The Me-esters, L----~lu- 
Leu-Pro-OCH3 (2)and Glu Thi -Pro-OCH3 (4) 
were previously found inactive, when tested in vivo 
for release of TSH and prolactin together with 
analogs 1,3 and additional six new tripeptides [ 12]. 
The results of the TSH induced release by the analogs 
when assayed in vitro are summarized in table 2. In 
the in vitro system Thi 2-TRFI  (3) has as much as 
77% of the activity of TRH, while Leu 2 -TRH (2) has 
similar potency as in the in vivo study or about 3%. 
The Me-esters, 2 and 4 are essentially inactive 
(table 2). 
After comparisons between the pKa values and 
biological potencies of TRH and analogs of TRH 
Grant et al. [6] suggested a preferred conformation of 
TRH having a hydrogen bond between the imidazol 
nN and the histidyl aN-H.  From results of NMR 
studies Fermandjian etal. [7] proposed a similar con- 
formation for the His moiety. Burgess et al. [11 ] 
more recently suggested a somewhat different con- 
formation of TRH from results obtained on confor- 
mational energy calculations of TRH and several of 
its analogs. Their data imply that in the low energy 
forms the central His moiety is in an extended con- 
formation, which means that the imidazole ring is 
directed away from the other atoms. They also sug- 
gest that a seven membered hydrogen bonded ring 
Table 1 
Assay of 2 tripeptides by the T3-method in vivo in mice 
Tripeptide Dose in ng 1125 a cpm a Rel. activity % 
TRH 1 2.306 
3 5.332 100 
9 11.178 
~-~Glu- Leu- Pro- NH 2 (1) 10 240 
30 606 2 
100 4.110 
~31u-Thi -  Pro-NH 2 (3) 10 5.110 30 
100 10.007 
Saline - 470 - 
a Each result is the mean value of 5 mice. 
Table 2 
In vitro TSH releasing activity of tripeptides a 
Dose Activity 
ng/ml ng TStt/ml Activity/ 
Peptides medium medium/hr Dose 
TRH 0.3 30.000 1.0 × 105 
~-t31u-Leu-Pro-NH 2 (1) 10.0 33.250 3.3 X 10 3 
~Glu-Leu-Pro-OCH 3 (2) 5.0 X 104 ?.500 1.5 X 10 -1 
~31u-Thi-Pro-NH 2 (3) 0.3 23.000 7.7 X 10 4 
EZJGlu-Thi-Pro-OCH3 (4) 5.0 X l04 23.000 4.6 X 10 -1 
a Two hourly pre-incubation a d 4 hourly incubation periods during peptide stimulation. 
Activity = mean results of 2 consecutive stimulations periods. Mean TSH release during 
pre-incubation periods ranged 3000-7000 ng TSHIml medium/hr. 
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is fc~rmed between the C-terminal N -H  and the 
oxygen in the peptide bond between His and Pro [11]. 
The latter also has been proposed by Fermandjian 
et al. [7]. 
Replacement of the imidazole ring of the His 
residue with a lipophilic aliphatic carbon side chain 
as in peptide I not only changes the over all charge 
of the molecule but also excludes any possibility of 
forming an internal hydrogen bond with the side 
chain. Also Thi 2 -TRH (3) having the essentially 
neutral aromatic thienyl side chain in the second 
position probably is uncharged at a physiological pH. 
Nevertheless I and 3 are remarkably potent analogs 
of TRH suggesting that for hormonal activity the side 
chain in position two is not confined into a single 
conformation due to a side chain backbone inter- 
action. The necessity of a side chain has been 
evidenced by the inactivity of Gly 2 -TRH [12]. 
The importance of aromaticity and special sterical 
requirements of the second amino acid of TRH might 
explain the differences in potencies between I and 3 
(tables 1 and 2). The lack of basicity in Thi 2 -TRH 
(3) is probably the reason why this analog is less 
potent han TRH. We have previously proposed the 
same interpretation to explain the decreased 
activity of Phe2-TRH, an analog having up to 10% 
of the activity of TRH [15]. 
If the inactivity of  the Me-esters, 2 and 4, reflect 
the inability of these analogs to form the seven mem- 
bered ring between the C-terminal N -H  and the 
previous peptide bond [7,11 ] then this requirement 
is extremely important for activity. The modification 
of TRH to its corresponding Me-ester will greatly 
diminishes its hormonal activity [3 -5] .  However, it 
cannot be excluded, as pointed out by Burgess et al. 
[11 ], that such a modification might cause a sterically 
unfavourable interaction at the receptor site, 'since ne 
large changes in the conformation of the rest of  the 
structure would be expected'. To be considered is
that the tetrapeptide ~ 'G lu -H is -P ro -G ly -NH2 has 
30% of the activity of TRH when tested in vivo in 
mice [ 16]. 
Just like TRH peptides 1 and 3 increased the 
serum levels of prolactin when tested in monkeys 
[12]. 
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